Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four

#ARQT Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

www.stocktitan.net/news/ARQT/arcutis-presen...

New Arcutis trial tests immune-checkpoint drug for atopic dermatitis First-in-human Phase 1a/1b study will gauge safety, tolerability and proof of concept for ARQ-234, a subcutaneous CD200R agonist in atopic dermatitis.

#ARQT Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

www.stocktitan.net/news/ARQT/arcutis-begins...

#ARQT #bd1cd5bb-c892-4de6-a7c9-2df33e5566ec #earningscall-transcripts

Origin | Interest | Match

Just In: ( NASDAQ: #ARQT ) This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit

Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa Arcutis (Nasdaq: ARQT) announced on January 23, 2026 that it and Kowa mutually agreed to terminate their promotion agreement for ZORYVE promotion to primary care physicians and pediatricians in the U.S.Arcutis will assume responsibility for sales and promotion to those clinicians, is finalizing promotional plans, and will provide further detail on the Q4 earnings call on February 25, 2026. Under the termination, Kowa will stop promotion and Arcutis will not be required to make any further payments. The company expects to remain cash flow break even and does not expect the change to negatively affect 2026 net product sales guidance.

#ARQT Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa

www.stocktitan.net/news/ARQT/arcutis-biothe...

Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones Arcutis (Nasdaq: ARQT) outlined 2026 strategic priorities focused on expanding the commercial footprint of ZORYVE and advancing its pipeline. Management reiterated full-year ZORYVE net product sales guidance of $455–$470 million and plans a targeted ~20% dermatology sales force expansion. Key development milestones include topline INTEGUMENT-INFANT Phase 2 results in Q1 2026 and an expected sNDA submission in Q3 2026 for ZORYVE cream 0.05% in infants; an FDA PDUFA target action date of June 29, 2026 for the sNDA for ZORYVE cream 0.3% in ages 2–5; Phase 2 proof‑of‑concept trials in vitiligo and hidradenitis suppurativa with program decisions in Q4 2026 and Q1 2027; and initiation of Phase 1 enrollment for ARQ-234 in Q1 2026. The company cited a transition to positive cash flows to fund growth and pipeline investment.

#ARQT Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones

www.stocktitan.net/news/ARQT/arcutis-highli...

🚨 Institutions #optionsvolume surge detected! Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ARQT 7.1x
2. #PBR 2.6x
3. #RZLT 2.4x
4. #HBM 2.2x
5. #SBSW 2.1x

#OptionFlow #OptionsTrading #Trading

News; ( NASDAQ: #ARQT ) This Biotech Stock Could Cure Your Portfolio's Pain

Breaking News: ( NASDAQ: #ARQT ) ARQT Price Target Alert: $37.00. Issued by Mizuho Securities

Breaking News: ( NASDAQ: #ARQT ) Why Shares in Arcutis Biotherapeutics Surged Again This Week

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis Arcutis (Nasdaq: ARQT) completed enrollment in the INTEGUMENT-INFANT Phase 2 open-label study evaluating investigational ZORYVE (roflumilast) cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis.Topline results are anticipated in Q1 2026. The U.S. FDA approved ZORYVE cream 0.05% for children ages 2 to 5 years in October 2025. The company described the cream as a selective topical PDE4 inhibitor formulated for delicate infant skin and noted strong enrollment interest from parents.

#ARQT Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

www.stocktitan.net/news/ARQT/arcutis-comple...

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #AMKR 24.8x
2. #JBLU 16.4x
3. #LYFT 7.0x
4. #TEVA 6.4x
5. #ARQT 6.1x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ARQT, #QFIN, #WHR, #CINF, #LEG

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #JBLU 9.4x
2. #ARQT 5.0x
3. #QFIN 2.9x
4. #PYPL 2.6x
5. #WHR 2.6x

#OptionFlow #OptionsTrading #Trading

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and Drug Administration (FDA) approval for the treatment of atopic dermatitis in children down to 2 years

#ARQT Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

www.stocktitan.net/news/ARQT/arcutis-outlin...

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere on the body for any duration About 1.8 million children ages 2 to 5 with atopic dermatitis are

#ARQT FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

www.stocktitan.net/news/ARQT/fda-approves-a...

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 Arcutis Biotherapeutics (NASDAQ:ARQT) has submitted a supplemental New Drug Application (sNDA) to the FDA to expand the indication of ZORYVE® (roflumilast) cream 0.3% for treating plaque psoriasis in children ages 2 to 5. Currently approved for adults and children aged 6 and above, if approved, ZORYVE would become the first topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2.The sNDA submission is supported by data from a 4-week Maximal Usage Systemic Exposure (MUSE) study in children aged 2-5 years and a long-term open-label study. The once-daily, steroid-free cream has demonstrated consistent favorable long-term safety, tolerability, and efficacy across age ranges, particularly beneficial for sensitive areas like intertriginous skin where psoriasis commonly presents in children.

#ARQT Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

www.stocktitan.net/news/ARQT/arcutis-submit...

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update Arcutis Biotherapeutics (Nasdaq: ARQT) reported strong Q2 2025 financial results, with net product revenue of $81.5 million, representing a 164% year-over-year increase and 28% sequential growth. The quarter was marked by significant achievements, including FDA approval of ZORYVE foam 0.3% for plaque psoriasis treatment and the initiation of the INTEGUMENT-INFANT study for ZORYVE cream in infants with atopic dermatitis.Key financial metrics include reduced net loss of $15.9 million ($0.13 per share) compared to $52.3 million in Q2 2024, with cash reserves of $191.1 million. The company's ZORYVE portfolio showed strong performance across all formulations, with over 1 million total prescriptions dispensed to date. Additionally, Arcutis submitted an IND for ARQ-234, a novel fusion protein for atopic dermatitis treatment.

#ARQT Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/ARQT/arcutis-announ...

June wrapped with a 4.73% gain, led by Newsletter 1 and Newsletter 11 surging over 10%. Even the S&P played catch-up this time. 🐸🌲🌴

#HWM #NFLX #ARQT

ZORYVE Becomes Only Branded Topical to Earn Strong AAD Recommendation for Atopic Dermatitis AAD's updated guidelines endorse ZORYVE as next-generation treatment for 16M+ adult atopic dermatitis patients. See efficacy data and clinical advantages.

#ARQT Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

www.stocktitan.net/news/ARQT/arcutis-zoryve...

Newsletter 2 took the spotlight with a sharp +0.99% gain, leading a green-tinged day across the board. Newsletter 10 followed with +0.76%, while the rest posted modest climbs. Despite the overall portfolio dipping -0.18%, pockets of strength are still shining through. 🚨👺🍓

#ARQT #MELI #URBN

Lots of green on the board today 🌲🌴🐸

Newsletter 2 leads the charge with a 3.7% gain, pushing the portfolio to a solid +0.85% on the day. Even the lighter weights showed muscle.

#ARQT #MELI #PLTR

Today’s rally was led by Newsletter 2, surging 4.21% and outpacing the pack. Newsletter 8 and 3 followed with solid gains. A broad-based bounce with some standout moves. 🐸🌴🌲

#ARQT #MELI #PLTR

Weekly wrap: modest uptick overall, with Newsletter 9 leading the charge at +3.81%. Green across the board, but the pie’s still got a sour slice—portfolio barely flat at -0.07%. 🍓👺🚨

Have a great weekend! ✌️

#DRI #ARQT #NFLX

Green shoots today 🐸🌲🌴 — Newsletter 2 surged +3.09%, leading the charge. Newsletter 3 held strong with a +1.28% gain, while others inched up modestly. Total portfolio? A quiet but welcome +0.10%.

#ARQT #PLTR #MELI

Breakthrough: New Eczema Treatment Trial Launches for 3-Month-Old Infants, Targeting 9.6M Children Phase 2 trial evaluates novel once-daily cream for infants as young as 3 months with atopic dermatitis. See how this addresses critical treatment gap.

#ARQT Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

www.stocktitan.net/news/ARQT/arcutis-enroll...

Newsletter 2 came out swinging this week with a blazing +10.2% return 🌲🌴🐸

Other standouts:
— Newsletter 5: +4.91%
— Newsletter 1: +4.62%
— S&P 500: +1.66%

Total portfolio gained +0.76% on the week — steady climb continues

#ARQT #AU #HWM

Strong day under the surface, even as the overall portfolio dipped 1.01% 🚨🍓👺

Standouts:
• Newsletter 5: +2.09%
• Newsletter 6: +2.08%
• Newsletter 2: +1.82%

Some in the green—just not the heavyweights.

#AU #ARQT #T